About Locus Biosciences
Locus Biosciences is a clinical-stage biotechnology company developing CRISPR-enhanced precision antibacterial products (crPhage™) to address critical unmet medical needs in bacterial infections and microbiome indications in oncology, immunology and neurology therapeutic areas. The Locus platform combines CRISPR-Cas3, which permanently degrades target DNA within a bacterial cell, with bacterial viruses called bacteriophages to specifically kill target pathogens while leaving non-target bacteria (i.e., the rest of the patient’s microbiome) unharmed. Locus completed its first human clinical trial in early 2021, with a crPhage product targeting Escherichia coli bacteria in the urinary tract. Locus also recently announced strategic collaborations with Johnson & Johnson, BARDA, and CARB-X to develop crPhage products targeting respiratory infections, E. coli urinary tract infections, and Klebsiella pneumoniae infections, respectively. For more information about Locus visit https://www.locus-bio.com/
Why Locus Biosciences?
- Change the future of medicine and address a serious and unmet patient need by developing a completely novel therapeutic modality using CRISPR/Cas technology
- Fasttrack your career by tackling large & meaningful projects
- Work with a team of exceptionally talented and hardworking individuals while striving to achieve a common mission
- Partner with the most highly respected pharmas in the world
- Stock options & bonus pool eligibility
- Health, dental, vision, life insurance, 401(k), and PTO
- Free gym membership